AUSTIN, Texas, Nov. 04, 2026 (GLOBE NEWSWIRE) — Wall Street Investor News Commentary – For most of the history of antibody discovery, the hard part was producing candidates. Generative models, high-throughput assays and automated labs have changed that, and the industry is running into a different limit. Every program generates sequences, structures, assay readouts and failed designs, and much of that record never travels cleanly into the next program. Drug developers, lab-tools makers and chip suppliers are now building around the problem, and the announcements of recent weeks show where the engineering effort is going. Companies mentioned in today’s commentary include: MindWalk Holdings Corp. (NASDAQ: HYFT), Advanced Micro Devices, Inc. (NASDAQ: AMD), NVIDIA Corporation (NASDAQ: NVDA), Danaher Corporation (NYSE: DHR), Twist Bioscience Corporation (NASDAQ: TWST).
Regulators Want to See the Evidence Trail
Pressure is also coming from Washington. On April 10, 2025, the FDA announced a plan to phase out the animal testing requirement for monoclonal antibodies and other drugs, pointing to approaches that include AI-based computational models of toxicity and encouraging sponsors to include data from these new approach methodologies in investigational new drug applications. In its one-year progress report, published in April 2026, the agency said it had qualified its first artificial intelligence-based drug development tool.
The FDA has also set out how it expects AI to be judged. Its January 2025 draft guidance on AI used to support regulatory decisions for drug and biological products describes a risk-based framework for establishing the credibility of an AI model for a defined context of use, and the agency’s website still lists that guidance as a draft. For a model’s output to hold up under that kind of review, the data behind it has to be traceable: where it came from, who approved its use, and what happened the last time a similar design went into the lab.
A Context Layer Moves Into the Discovery Workflow
MindWalk Holdings Corp. (NASDAQ: HYFT), a Bio-Native AI company, has announced a multi-year agreement with Teva Pharmaceuticals Australia Pty Ltd (“Teva Australia”) to deploy ReefIQ™, MindWalk’s biological context layer powered by HYFT® Technology, with specified LensAI™ analytical capabilities, in support of a defined scope of antibody-discovery work. Teva Australia scientists will use the AI capabilities to support discovery decisions based on generated predictions and accelerate antibody design optimization. MindWalk has worked with Teva Australia since 2018. Under the agreement, MindWalk will provide authorized analysis of approved data sources within the agreed scope, and deployment and use will be subject to Teva’s applicable information-security, privacy, data-governance, scientific-review and human-oversight requirements. Financial terms were not disclosed.
“Across the industry, the constraint in antibody discovery is no longer generating data. It is connecting and governing that data and carrying what a program team learns to the next phase,” said Jennifer Bath, PhD, President and Chief Executive Officer of MindWalk. “That is exactly what ReefIQ was built to do for companies.” MindWalk describes the agreement as the kind of recurring-revenue platform relationship it told the market to expect: a multi-year relationship that supports scientists as programs advance within the agreed scope, rather than a fee-for-service project that ends when the deliverable is shipped or a software subscription priced by the seat. ReefIQ draws on HYFT’s biological representation of 660 million biological patterns and 25 billion relationships, refined over 20 years of curation, and the company says it is in active discussions with additional life sciences organizations regarding ReefIQ deployments.
CONTINUED… Read this and more news for MindWalk Holdings Corp. at: wsi.news
The Labs Producing the Data
Danaher Corporation (NYSE: DHR) is attacking the same problem from the wet-lab side. On October 7, it announced a new AI-powered autonomous lab, based at its Abcam business, that uses AI to design new affinity reagents, including antibodies, then builds and tests each one and feeds the results back into the model to improve the next design. Danaher says the lab is designed to deliver up to 8x faster discovery of affinity reagents and up to a tenfold increase in annual reagent generation, and expects it to operate at scale in early 2027. The data foundation is already being laid: in September, Abcam and Genedata, another Danaher company, announced the deployment of Genedata Biologics across Abcam’s global R&D organization to create a unified data foundation for antibody development. Danaher also reported third-quarter revenues up 8.5% year over year to $6.6 billion and raised its full-year adjusted diluted EPS guidance to $8.57 to $8.62.
“This lab represents a new model for scientific discovery, where AI, automation and human expertise work together in a continuous learning cycle,” said JC Gutierrez-Ramos, Senior Vice President and Chief Science Officer of Danaher. “Speed is what supercharges that cycle. Every result sharpens the next design, so the faster each loop runs, the faster discovery compounds.”
Twist Bioscience Corporation (NASDAQ: TWST) is supplying the measurements that AI models train on. In September, Twist joined Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company, as a provider of antibody characterization data services, including for AbLab, an antibody developability prediction model. TuneLab users can order Twist antibody services that follow TuneLab-preferred protocols and send the resulting wet-lab data back to TuneLab for federated training. Twist reported fiscal third-quarter revenue of $118.4 million, its fourteenth consecutive quarter of growth, raised its fiscal 2026 revenue guidance to $456 million to $457 million, and will report fiscal fourth-quarter and full-year results before the market opens on November 12, 2026.
“The quality of an AI model’s output depends on the quality of the data used to train it,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Twist has the scale and high-throughput capabilities to generate consistent and reliable antibody characterization data these models need to be trained on.”
The Silicon Doing the Arithmetic
NVIDIA Corporation (NASDAQ: NVDA) is putting open models into the loop. At GTC Berlin on October 21, NVIDIA and the UW Medicine Institute for Protein Design released RFD4-Proteina, an open BioNeMo model that pairs programmable protein design with search, and Genedata’s AI co-scientist will use it to coordinate protein design and testing in a protein design foundry within Danaher’s autonomous lab. NVIDIA reported second-quarter fiscal 2027 revenue of $96.2 billion, up 106% from a year earlier, including Data Center revenue of $89.0 billion, and expects third-quarter revenue of $108.0 billion, plus or minus 2%.
“Agentic and physical AI are opening new possibilities across medicine, from designing proteins and powering autonomous laboratories to improving personalized cancer care,” said Kimberly Powell, vice president of healthcare at NVIDIA.
Advanced Micro Devices, Inc. (NASDAQ: AMD) reported record second-quarter 2026 revenue of $11.5 billion, up 50% year over year, with Data Center segment revenue of $6.7 billion, up 107%, on strong demand for AMD EPYC™ processors and AMD Instinct™ GPUs. On September 28, it agreed to acquire World Labs in an all-stock transaction valued at approximately $8.2 billion, expected to close by the end of 2026, subject to regulatory approvals and other customary closing conditions. AMD has also published a case study on MindWalk’s use of its Instinct GPUs and EPYC processors in AI drug discovery, and will report third-quarter results after the market close on November 3, 2026.
“Building the compute platforms for the next generation of AI requires a deep understanding of how models are evolving,” said Dr. Lisa Su, chair and CEO, AMD. “Fei-Fei and the World Labs team bring exceptional research leadership and model expertise.”
What to Watch
The next few weeks bring a run of updates across the group: AMD’s third-quarter report on November 3 and Twist’s fiscal fourth-quarter results on November 12, with Danaher’s autonomous lab expected to operate at scale in early 2027. For MindWalk, the markers are progress on the Teva Australia deployment and any further ReefIQ agreements to come out of its discussions with other life sciences organizations. As MindWalk puts it, AI models turn over while the context layer accumulates.
Track the Signals Before the Crowd
The best positioning happens before the crowd catches on. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow, and trending tickers as they form, so you see attention building instead of chasing it. Watch it live at eagle-eye.dev.
Article Source: MindWalk Holdings Corp. news release announcing a multi-year agreement with Teva Pharmaceuticals Australia Pty Ltd.
Contact Information:
wsi.news
Media Contact: info@wsi.news
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor a recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.
This article is being distributed by Wall Street Investor (wsi.news), a property of a joint venture between Market Equities Limited, a company incorporated under the laws of Ireland (“MEL”), and Mining Stock, LLC, a Tennessee limited liability company (“Mining Stock”), under which MEL and Mining Stock share in the net profits of the joint venture. MEL has been paid a fee for MindWalk Holdings Corp. advertising and digital media distribution from Creative Direct Marketing Group (“CDMG”), and compensation received in connection with this article may be shared with Mining Stock under the terms of the joint venture. MEL has not been paid a fee directly by MindWalk Holdings Corp., and MEL is not affiliated with, and is a separate and independent entity from, CDMG and MindWalk Holdings Corp. MEL also expects to receive further compensation as part of an ongoing digital media effort to increase visibility for the company. No further notice will be given, but let this disclaimer serve as notice that all material, including this article, has been reviewed and approved by MindWalk Holdings Corp. and CDMG.
This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision.
MEL and its owners, operators, directors, and affiliates do not currently own any shares of MindWalk Holdings Corp., but reserve the right to, and will, buy and sell shares of MindWalk Holdings Corp. at any time without further notice, commencing immediately and ongoing, in the open market, through private placements, and/or through other investment vehicles. Mining Stock and its principals may, from time to time, hold positions in securities mentioned in this article. There may also be third parties who hold shares of MindWalk Holdings Corp. and may liquidate their shares, which could have a negative effect on the price of the stock.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this publication is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful: investing in securities carries a high degree of risk, and you may lose some or all of your investment.
Cautionary Note Regarding Company Statements and the Teva Australia Agreement. Statements in this article about the agreement with Teva Pharmaceuticals Australia Pty Ltd and about the capabilities and design of ReefIQ™, LensAI™ and HYFT® Technology are drawn from MindWalk Holdings Corp.’s own announcement and have not been independently verified by us. The agreement covers a defined deployment within an agreed scope, its financial terms were not disclosed, and deployment and use are subject to Teva’s information-security, privacy, data-governance, scientific-review and human-oversight requirements. There is no assurance that the agreement will generate recurring revenue at any particular level, that it will not be terminated, not renewed, or renewed on different terms, or that its scope will not change, and there is no assurance that the Company’s discussions with other life sciences organizations will result in additional agreements. AI-generated predictions are statistical in nature and do not guarantee discovery, clinical or commercial outcomes. References to Teva Pharmaceuticals Australia Pty Ltd do not imply that it has reviewed or endorsed this article. References to Advanced Micro Devices, Inc. and NVIDIA Corporation describe compute products and initiatives drawn from those companies’ public disclosures and are not MindWalk product claims; according to AMD, the performance and cost claims in its MindWalk case study were provided by MindWalk and have not been independently verified by AMD. No such reference implies endorsement, sponsorship or partnership. References to FDA initiatives describe the regulatory environment generally; the FDA’s AI guidance referenced is a draft, and nothing in this article indicates regulatory acceptance of any company’s product or method. Results and plans of other companies referenced in this article are as reported by those companies and are not indicative of MindWalk Holdings Corp.’s prospects. Additional information is available in the Company’s Annual Report on Form 20-F and other filings on SEDAR+ (www.sedarplus.ca) and EDGAR (www.sec.gov).
Trademarks. HYFT® is a registered trademark of MindWalk Holdings Corp. ReefIQ™ and LensAI™ are trademarks of MindWalk Holdings Corp.; ReefIQ™ registration is pending. All other marks referenced in this article are the property of their respective owners.
Eagle Eye Disclosure. Eagle Eye is an investor signal-intelligence platform affiliated with the publisher of this article, and this reference constitutes promotion of an affiliated product. Eagle Eye is not a broker-dealer, and nothing in the platform or in this article is financial, investment, tax, or legal advice. Data provided in the platform is for informational purposes only and may be delayed. Always do your own research before making any investment decision.
Forward-Looking Statements: This publication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K, 20-F or 10-Q and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this publication are made as of the date hereof and MEL undertakes no obligation to update such statements.
SOURCE Wall Street Investor
Media gallery
